Shaping the Future of Acromegaly Care

This educational podcast series is intended for US healthcare professionals only. It was developed by expert faculty in collaboration with The Pituitary Society and Amiculum, with support from Recordati Rare Diseases through an independent educational grant. Recordati Rare Diseases had no involvement in content development, speaker selection, or editorial decisions. Discussions in this series are informed by the 2025 consensus on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37). Speaker disclosures: Maria Fleseriu (Oregon Health and Science University, Portland, USA) Research grants to her university from Crinetics Pharmaceuticals and Debio. Scientific consulting fees from Crinetics Pharmaceuticals, Camurus AB, Marea and Recordati Rare Diseases. Shlomo Melmed (Cedars-Sinai Pituitary Center, Los Angeles, USA) Consulting honoraria and speaker fees from Camurus AB, Marea Therapeutics, Novo Nordisk and Recordati Rare Diseases. Mark Gurnell (University of Cambridge School of Clinical Medicine, Cambridge, England) Consulting honoraria and speaker fees from Camurus AB, Marea Therapeutics and Recordati Rare Diseases. Mônica Gadelha (Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil) Advisory board member for Camurus AB, Crinetics Pharmaceuticals, Novo Nordisk and Recordati Rare Diseases. Research investigator for Crinetics Pharmaceuticals and Recordati Rare Diseases. Speaker for Camurus AB, Crinetics Pharmaceuticals, Novo Nordisk and Recordati Rare Diseases.